Virginia Bottomley - Smith Nephew Non-Executive Independent Director
SNN Stock | USD 23.88 0.69 2.81% |
Director
Rt. Hon. Baroness Virginia Hilda Brunette Maxwell Bottomley is NonExecutive Independent Director of Smith Nephew PLC., since April 12, 2012. She is a Member of the Remuneration Committee and Nomination Governance Committee in April 2014 and will join the Compliance Culture Committee in April 2019. Career and experience Virginia gained her MSc in Social Administration from the London School of Economics following her first degree. She was appointed a Life Peer in 2005 following her career as a Member of Parliament between 1984 and 2005. She served successively as Secretary of State for Health and then Culture, Media and Sport. Virginia was formerly a Director of Bupa and AkzoNobel NV. She is currently a Director of International Resources Group Limited, where she is Chair of Board CEO Practice at Odgers Berndtson. She is a member of the International Advisory Council of Chugai Pharmaceutical Co., Chancellor of University of Hull and Sheriff of Kingston upon Hull. She is a Trustee of The Economist Newspaper. Skills and competencies Virginias extensive experience within Government, particularly as Secretary of State for Health, brings a unique insight into the healthcare system both in the UK and globally, whilst her experience on the board of Bupa brings an understanding of the private healthcare sector and an insight into the needs of our customers. Her experience running the board practice at a search firm gives her a valuable skillset as a member of the Nomination Governance Committee and Remuneration Committee. Her long association with Hull, the home of many of our UK employees, also brings an added perspective. since 2012.
Age | 72 |
Tenure | 12 years |
Address | Building 5, Watford, United Kingdom, WD18 8YE |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has Return on Asset of 0.0427 % which means that on every $100 spent on assets, it made $0.0427 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0502 %, implying that it generated $0.0502 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of April 2024, Return On Tangible Assets is likely to drop to 0.04. In addition to that, Return On Capital Employed is likely to drop to 0.12. At this time, Smith Nephew's Total Assets are very stable compared to the past year. As of the 26th of April 2024, Non Current Assets Total is likely to grow to about 6.3 B, while Other Current Assets are likely to drop about 87.4 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
William Linton | Bruker | 70 | |
Marie Infante | Orthopediatrics Corp | 68 | |
lan Molson | Alphatec Holdings | 61 | |
James Hinrichs | Integer Holdings Corp | 53 | |
Bruce Bodaken | iRhythm Technologies | 66 | |
Gilles Martin | Bruker | 54 | |
Guy Jordan | Orthofix Medical | 65 | |
Maria Sainz | Orthofix Medical | 51 | |
Siri Marshall | Alphatec Holdings | 66 | |
Peter Soderberg | Integer Holdings Corp | 71 | |
Peter Munson | Orthopediatrics Corp | 49 | |
William Summers | Integer Holdings Corp | 70 | |
Stefano Gianotti | LivaNova PLC | 53 | |
James Tobin | Globus Medical | 75 | |
Donald Spence | Integer Holdings Corp | 67 | |
David Davidar | Globus Medical | 54 | |
Ralph Snyderman | iRhythm Technologies | 78 | |
John Ornell | Bruker | 60 | |
Dirk Kuyper | CONMED | 61 | |
Lilly Marks | Orthofix Medical | 69 | |
Filippo Passerini | Integer Holdings Corp | 63 |
Management Performance
Return On Equity | 0.0502 | ||||
Return On Asset | 0.0427 |
Smith Nephew SNATS Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Friedman, Non-Executive Independent Director | ||
Helen Barraclough, Company Counsel | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Chief Executive Officer, Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Independent Director | ||
Simon Fraser, President - Advanced Wound Management and Global Commercial Operations | ||
John Rogers, CFO Director | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, Chief Financial Officer, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Ian Melling, Interim Chief Financial Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, Senior Communications | ||
Rick Medlock, Non-Executive Independent Director | ||
Glenn Warner, President - Advanced Wound Management | ||
Paul Connolly, President Operations | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Independent Director | ||
Mark Gladwell, President - Global Operations and Global Business Services | ||
John Ma, Non-Executive Independent Director | ||
Vasant Padmanabhan, President - Research & Development | ||
Joseph Papa, Non-Executive Independent Director | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Ian Barlow, Non-Executive Independent Director | ||
Namal Nawana, Chief Executive Officer, Executive Director | ||
Bob White, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Independent Director | ||
Deepak Nath, Chief Executive Officer | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Independent Director | ||
AnneFrancoise Nesmes, Chief Financial Officer, Executive Director | ||
Rodrigo Bianchi, Interim President - Asia Pacific | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, President Orthopaedics | ||
Katarzyna MazurHofsaess, Non-Executive Independent Director | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Peter Coenen, President - EMEA Region | ||
Robin Freestone, Senior Non-Executive Independent Director | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Myra Eskes, President - Asia Pacific | ||
Andrew Swift, Vice Relations | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Ingeborg Oie, VP, Investor Relations | ||
Steve Kane, Global US | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President - Sports Medicine & ENT | ||
Jo Hallas, Non-Executive Director | ||
Catheryn ORourke, Chief Legal and Compliance Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0502 | ||||
Return On Asset | 0.0427 | ||||
Profit Margin | 0.05 % | ||||
Operating Margin | 0.14 % | ||||
Current Valuation | 24.2 B | ||||
Shares Outstanding | 437.17 M | ||||
Shares Owned By Insiders | 0.03 % | ||||
Shares Owned By Institutions | 7.56 % | ||||
Number Of Shares Shorted | 1.98 M | ||||
Price To Earning | 25.42 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.
Currently Active Assets on Macroaxis
When determining whether Smith Nephew SNATS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Smith Nephew's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Smith Nephew Snats Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Smith Nephew Snats Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Smith Stock analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
CEOs Directory Screen CEOs from public companies around the world |
Is Smith Nephew's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.983 | Dividend Share 0.375 | Earnings Share 0.6 | Revenue Per Share 2.5484 | Quarterly Revenue Growth 0.076 |
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.